SphynKx Therapeutics LLC, is a privately held biotechnology company based in Charlottesville, VA. We are focused on discovering, developing, and commercializing novel sphingosine kinase (SphK) inhibitors for the treatment of fibrosis. Nearly 45% of deaths in the United States can be attributed to disorders with a significant fibrotic component, yet there are no FDA-approved therapies to treat this pathology. Our team possesses world-class expertise in the field of SphK chemical biology and our drug discovery platform has generated a portfolio of potent and selective sphingosine kinase inhibitors with promising pre-clinical activity. Our pipeline includes both SphK1 and SphK2-selective inhibitors.
SphynKx Therapeutics LLC Featured in BioCentury Emerging
SphynKx Therapeutics LLC Awarded National Institutes of Health Grant to Advance Novel Sphingosine Kinase 2 Inhibitors
SphynKx Therapeutics LLC Awarded SBIR Match Award From the Commonwealth Research Commercialization Fund (CRCF)
SphynKx Therapeutics LLC Accepted into 2013 Class of MindShare
SphynKx Therapeutics LLC Co-Founder and CEO Named a GAP 50 Finalist
SphynKx Therapeutics LLC Awarded National Institutes of Health Grant to Advance Novel Sphingosine Kinase Inhibitors